[go: up one dir, main page]

JOP20160086B1 - مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك - Google Patents

مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك

Info

Publication number
JOP20160086B1
JOP20160086B1 JOP/2016/0086A JOP20160086A JOP20160086B1 JO P20160086 B1 JOP20160086 B1 JO P20160086B1 JO P20160086 A JOP20160086 A JO P20160086A JO P20160086 B1 JOP20160086 B1 JO P20160086B1
Authority
JO
Jordan
Prior art keywords
compounds
mono
substituted indole
viral replication
indole derivatives
Prior art date
Application number
JOP/2016/0086A
Other languages
English (en)
Inventor
Bart Rudolf Romanie Kesteleyn
Jean-François Bonfanti
Tim Hugo Maria Jonckers
Pierre Jean-Marie Bernard Raboisson
Dorothée Alice Marie-Eve Bardiot
Arnaud Didier M Marchand
Original Assignee
2 Katholieke Univ Leuven Ku Leuven Research And Development
Janssen Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 2 Katholieke Univ Leuven Ku Leuven Research And Development, Janssen Pharmaceuticals Inc filed Critical 2 Katholieke Univ Leuven Ku Leuven Research And Development
Application granted granted Critical
Publication of JOP20160086B1 publication Critical patent/JOP20160086B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/08—Bridged systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

يتعلق الاختراع الحالي بمركبات اندول مستبدلة احاديا أو ثنائيا وبطرق لمنع او معالجة الاصابات الفيروسية باستخدام المركبات المذكورة. وكما يتعلق بالمركبات المذكورة بخصوص استخدامها كدواء والافضل لاستخدامها كعلاج لمنع أو معالجة الاصابات الفيروسية لحمى الفنك. كما يتعلق الاختراع الحالي بتركيبات صيدلانية أو مستحضرات متحدة من المركبات، وبالتركيبات أو المستحضرات لاستخدامها كدواء، والافضل لمنع أو معالجة الاصابات الفيروسية لحمى الفنك. كما يتعلق الاخراع بعمليات و طرق لتحضير هذه المركبات.
JOP/2016/0086A 2015-05-08 2016-05-03 مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك JOP20160086B1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15166900 2015-05-08
EP16163342 2016-03-31

Publications (1)

Publication Number Publication Date
JOP20160086B1 true JOP20160086B1 (ar) 2021-08-17

Family

ID=56026812

Family Applications (2)

Application Number Title Priority Date Filing Date
JOP/2016/0086A JOP20160086B1 (ar) 2015-05-08 2016-05-03 مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP/2021/0109A JOP20210109A1 (ar) 2015-05-08 2021-05-10 مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك

Family Applications After (1)

Application Number Title Priority Date Filing Date
JOP/2021/0109A JOP20210109A1 (ar) 2015-05-08 2021-05-10 مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك

Country Status (39)

Country Link
US (5) US10696632B2 (ar)
EP (2) EP3896072B1 (ar)
JP (4) JP6752821B2 (ar)
KR (2) KR102610491B1 (ar)
CN (3) CN113045476B (ar)
AU (2) AU2016259677B2 (ar)
BR (1) BR112017023904A2 (ar)
CA (1) CA2981845C (ar)
CL (1) CL2017002817A1 (ar)
CO (1) CO2017012381A2 (ar)
CR (2) CR20170490A (ar)
CY (1) CY1124548T1 (ar)
DK (1) DK3294738T3 (ar)
EA (1) EA034978B1 (ar)
EC (2) ECSP17073878A (ar)
ES (2) ES2877404T3 (ar)
GT (1) GT201700234A (ar)
HK (2) HK1252496A1 (ar)
HR (1) HRP20210675T1 (ar)
HU (1) HUE054724T2 (ar)
IL (2) IL255430B (ar)
JO (2) JOP20160086B1 (ar)
LT (1) LT3294738T (ar)
MD (1) MD3294738T2 (ar)
MX (2) MX391754B (ar)
NI (1) NI201700137A (ar)
PE (2) PE20221579A1 (ar)
PH (1) PH12017502000B1 (ar)
PL (1) PL3294738T3 (ar)
RS (1) RS62029B1 (ar)
SG (1) SG10201900315SA (ar)
SI (1) SI3294738T1 (ar)
SM (1) SMT202100367T1 (ar)
SV (1) SV2017005557A (ar)
TW (2) TWI725969B (ar)
UA (2) UA128183C2 (ar)
UY (2) UY36674A (ar)
WO (1) WO2016180696A1 (ar)
ZA (2) ZA201707524B (ar)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201116559D0 (en) 2011-09-26 2011-11-09 Univ Leuven Kath Novel viral replication inhibitors
GB201305376D0 (en) 2013-03-25 2013-05-08 Univ Leuven Kath Novel viral replication inhibitors
HRP20190139T1 (hr) * 2014-10-01 2019-03-22 Janssen Pharmaceuticals, Inc. Mono- ili di-supstituirani indoli kao inhibitori replikacije denga virusa
HRP20190199T1 (hr) * 2014-10-01 2019-04-05 Janssen Pharmaceuticals, Inc. Mono- ili di-supstituirani derivati indola kao inhibitori replikacije denga virusa
JOP20160086B1 (ar) 2015-05-08 2021-08-17 2 Katholieke Univ Leuven Ku Leuven Research And Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JO3633B1 (ar) 2015-09-16 2020-08-27 Katholieke Univ Leuven Ku Leuven Research & Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20160198B1 (ar) 2015-09-16 2022-03-14 Janssen Pharmaceuticals Inc مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
DK3436435T3 (da) 2016-03-31 2021-08-09 Janssen Pharmaceuticals Inc Substituerede indolderivater som inhibitorer af replikation af denguevirus
JP6931357B2 (ja) 2016-03-31 2021-09-01 ヤンセン ファーマシューティカルズ，インコーポレーテッド デングウイルス複製阻害剤としての置換インドリン誘導体
CR20180494A (es) * 2016-04-01 2019-01-29 Janssen Pharmaceuticals Inc Derivados de compuestos de indol sustituidos como inhibidores de la replicación vírica del dengue
JOP20170069B1 (ar) 2016-04-01 2021-08-17 1 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20180026A1 (ar) 2017-03-31 2019-01-30 Univ Leuven Kath مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20180025B1 (ar) 2017-03-31 2021-08-17 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
SI3630724T1 (sl) 2017-05-22 2021-08-31 Janssen Pharmaceuticals, Inc. Substituirani derivati indolina kot zaviralci replikacije virusa denga
JP7203764B2 (ja) 2017-05-22 2023-01-13 ヤンセン ファーマシューティカルズ，インコーポレーテッド デングウイルス複製阻害剤としての置換インドリン誘導体
IL292970A (en) * 2019-11-15 2022-07-01 Janssen Pharmaceuticals Inc Treatment and prevention of dengue disease
WO2022094817A1 (en) 2020-11-04 2022-05-12 Janssen Pharmaceuticals, Inc. Pharmaceutical formulation
WO2022094816A1 (en) * 2020-11-04 2022-05-12 Janssen Pharmaceuticals, Inc. Solid formulation
CN113024440B (zh) * 2021-03-17 2023-05-16 凯莱英医药集团（天津）股份有限公司 连续化合成取代吲哚-2-羧酸的方法
AU2022304189A1 (en) 2021-06-29 2024-02-15 Janssen Pharmaceuticals, Inc. Processes for the preparation of (s)-2-(4-chloro-2-methoxyphenyl)-2-((3-methoxy-5-(methylsulfonyl)phenyl)amino)-1 -(1h-indol-3-yl)ethenone derivatives
CN119173261A (zh) 2022-05-12 2024-12-20 杨森制药公司 登革热病毒感染的治疗和/或预防
CN115521307B (zh) * 2022-09-30 2023-09-22 甘肃皓天医药科技有限责任公司 一种5-卤代-7-氮杂吲哚的制备方法
CN119306651A (zh) * 2024-10-11 2025-01-14 山东大学 一种吲哚3-酰胺类衍生物及其制备方法与应用

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001520998A (ja) 1997-10-27 2001-11-06 イーライ・リリー・アンド・カンパニー インドールｓＰＬＡ２阻害剤のモルホリノ−Ｎ−エチルエステルプロドラッグ
GB0110832D0 (en) 2001-05-03 2001-06-27 Virogen Ltd Antiviral compounds
US20050074457A1 (en) 2001-12-12 2005-04-07 Adeela Kamal Assays and implements for determining and modulating hsp90 binding activity
GB0215293D0 (en) 2002-07-03 2002-08-14 Rega Foundation Viral inhibitors
KR20070098914A (ko) 2005-01-14 2007-10-05 제네랩스 테크놀로지스, 인코포레이티드 바이러스 감염을 치료하기 위한 인돌 유도체
EP1853317A2 (en) 2005-02-09 2007-11-14 Migenix Inc. Compositions and methods for treating or preventing flaviviridae infections
FR2928645A1 (fr) * 2008-03-14 2009-09-18 Sanofi Aventis Sa Nouveaux derives de carbazole inhibiteurs d'hsp90, compositions les contenant et utilisation
CN102056483A (zh) 2008-06-03 2011-05-11 西佳技术公司 用于治疗或预防登革病毒感染的小分子抑制剂
EA201170349A1 (ru) * 2008-08-18 2011-08-30 Йейл Юниверсити Модуляторы mif
JP5559174B2 (ja) 2008-08-19 2014-07-23 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 冷感−メントール受容体拮抗剤
TWI453207B (zh) 2008-09-08 2014-09-21 Signal Pharm Llc 胺基三唑并吡啶，其組合物及使用其之治療方法
WO2010091413A1 (en) 2009-02-09 2010-08-12 Enanta Pharmaceuticals, Inc. Linked dibenzimidazole derivatives
GB0910003D0 (en) 2009-06-11 2009-07-22 Univ Leuven Kath Novel compounds for the treatment of neurodegenerative diseases
US8993604B2 (en) 2009-06-30 2015-03-31 Siga Technologies, Inc. Treatment and prevention of dengue virus infections
KR20120123678A (ko) 2010-01-15 2012-11-09 길리애드 사이언시즈, 인코포레이티드 플라비비리다에 바이러스의 억제제
EP2552211A4 (en) 2010-03-26 2013-10-23 Glaxo Group Ltd INDAZOLYL-PYRIMIDINE AS KINASEHEMMER
JP5716205B2 (ja) 2011-03-29 2015-05-13 学校法人日本大学 グルコシダーゼ活性阻害用組成物及びそのスクリーニング方法
GB201116559D0 (en) * 2011-09-26 2011-11-09 Univ Leuven Kath Novel viral replication inhibitors
GB201305376D0 (en) 2013-03-25 2013-05-08 Univ Leuven Kath Novel viral replication inhibitors
KR102290189B1 (ko) 2013-10-23 2021-08-17 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 카르복스아미드 유도체 및 ｂ형 간염 치료용 의약으로서의 이의 용도
ES2893251T3 (es) 2014-01-31 2022-02-08 Bristol Myers Squibb Co Macrociclos con grupos P2’ heterocíclicos como inhibidores del factor XIa
CA3195249A1 (en) 2014-06-04 2015-12-10 Amgen Inc. Methods for harvesting mammalian cell cultures
CA2949981C (en) 2014-06-04 2023-03-14 Fred Hutchinson Cancer Research Center Expansion and engraftment of stem cells using notch 1 and/or notch 2 agonists
HRP20190199T1 (hr) 2014-10-01 2019-04-05 Janssen Pharmaceuticals, Inc. Mono- ili di-supstituirani derivati indola kao inhibitori replikacije denga virusa
NO2721243T3 (ar) 2014-10-01 2018-10-20
HRP20190139T1 (hr) 2014-10-01 2019-03-22 Janssen Pharmaceuticals, Inc. Mono- ili di-supstituirani indoli kao inhibitori replikacije denga virusa
US11180816B2 (en) 2014-10-10 2021-11-23 Rutgers, The State University Of New Jersey Polymerase chain reaction primers and probes for Mycobacterium tuberculosis
PH12017501272B1 (en) * 2015-01-16 2023-01-11 Janssen Pharmaceuticals Inc Indole derivatives as dengue viral replication inhibitors
AR103680A1 (es) 2015-02-23 2017-05-24 Lilly Co Eli Inhibidores selectivos de bace1
JOP20160086B1 (ar) * 2015-05-08 2021-08-17 2 Katholieke Univ Leuven Ku Leuven Research And Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
BR112018001164B1 (pt) 2015-07-22 2023-11-21 Omeicos Therapeutics Gmbh Composto, composição farmacêutica e uso de um composto ou uma composição farmacêutica
JOP20160198B1 (ar) 2015-09-16 2022-03-14 Janssen Pharmaceuticals Inc مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JO3633B1 (ar) 2015-09-16 2020-08-27 Katholieke Univ Leuven Ku Leuven Research & Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
PT3370698T (pt) 2015-11-03 2022-03-02 Zoetis Services Llc Compósitos de polímero sol-gel e utilizações dos mesmos
JP6931357B2 (ja) 2016-03-31 2021-09-01 ヤンセン ファーマシューティカルズ，インコーポレーテッド デングウイルス複製阻害剤としての置換インドリン誘導体
DK3436435T3 (da) 2016-03-31 2021-08-09 Janssen Pharmaceuticals Inc Substituerede indolderivater som inhibitorer af replikation af denguevirus
EA036637B1 (ru) 2016-03-31 2020-12-02 Такеда Фармасьютикал Компани Лимитед Гетероциклические спиросоединения, ингибирующие моноацилглицерин-липазу
PL3436457T3 (pl) 2016-04-01 2022-11-28 Basf Se Związki bicykliczne
CR20180494A (es) 2016-04-01 2019-01-29 Janssen Pharmaceuticals Inc Derivados de compuestos de indol sustituidos como inhibidores de la replicación vírica del dengue
CN109069512B (zh) 2016-04-01 2022-06-14 西格诺药品有限公司 取代的氨基嘌呤化合物、其组合物以及相关治疗方法
KR102731644B1 (ko) 2016-04-01 2024-11-19 카이트 파마 인코포레이티드 키메라 수용체 및 그의 사용 방법
JOP20170069B1 (ar) 2016-04-01 2021-08-17 1 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
SG11201808411RA (en) 2016-04-01 2018-10-30 Kite Pharma Inc Chimeric antigen and t cell receptors and methods of use
PE20190201A1 (es) 2016-04-01 2019-02-05 Amgen Inc Receptores quimericos de flt3 y metodos de uso de los mismos
JP6573745B2 (ja) 2017-03-17 2019-09-11 三菱電機株式会社 アダプティブアレーアンテナ装置
JOP20180025B1 (ar) 2017-03-31 2021-08-17 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20180026A1 (ar) 2017-03-31 2019-01-30 Univ Leuven Kath مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
SI3630724T1 (sl) 2017-05-22 2021-08-31 Janssen Pharmaceuticals, Inc. Substituirani derivati indolina kot zaviralci replikacije virusa denga
JP7203764B2 (ja) 2017-05-22 2023-01-13 ヤンセン ファーマシューティカルズ，インコーポレーテッド デングウイルス複製阻害剤としての置換インドリン誘導体

Also Published As

Publication number Publication date
AU2020273314B2 (en) 2021-10-21
GT201700234A (es) 2018-11-26
JP2022166289A (ja) 2022-11-01
US10919854B2 (en) 2021-02-16
US20210171462A1 (en) 2021-06-10
ES2877404T3 (es) 2021-11-16
IL272814B (en) 2021-02-28
MX383932B (es) 2025-03-14
CN111303000B (zh) 2023-11-28
JP6898493B2 (ja) 2021-07-07
CR20200152A (es) 2020-09-08
EP3896072A1 (en) 2021-10-20
PL3294738T3 (pl) 2021-12-13
AU2016259677B2 (en) 2020-10-01
PH12017502000A1 (en) 2018-03-26
CO2017012381A2 (es) 2018-03-28
KR102610493B1 (ko) 2023-12-05
MD3294738T2 (ro) 2021-08-31
NZ765879A (en) 2024-09-27
MX2020011156A (es) 2022-04-21
CY1124548T1 (el) 2022-07-22
IL255430B (en) 2020-03-31
KR20210048578A (ko) 2021-05-03
TWI725969B (zh) 2021-05-01
CN107873022A (zh) 2018-04-03
SG10201900315SA (en) 2019-02-27
JP7132399B2 (ja) 2022-09-06
EP3294738A1 (en) 2018-03-21
ZA201707524B (en) 2024-06-26
TWI744963B (zh) 2021-11-01
CN107873022B (zh) 2021-03-12
TW201704208A (zh) 2017-02-01
HK1252496A1 (zh) 2019-05-31
CA2981845A1 (en) 2016-11-17
US12172959B2 (en) 2024-12-24
US20240182414A1 (en) 2024-06-06
BR112017023904A2 (pt) 2018-07-17
JP6752821B2 (ja) 2020-09-09
CL2017002817A1 (es) 2018-05-11
AU2020273314A1 (en) 2020-12-17
HRP20210675T1 (hr) 2021-06-25
TW202041499A (zh) 2020-11-16
ECSP17073878A (es) 2018-02-28
EP3896072B1 (en) 2022-11-16
WO2016180696A1 (en) 2016-11-17
IL255430A0 (en) 2017-12-31
CN113045476A (zh) 2021-06-29
CA2981845C (en) 2022-03-08
RS62029B1 (sr) 2021-07-30
UY39706A (es) 2022-05-31
HUE054724T2 (hu) 2021-09-28
KR102610491B1 (ko) 2023-12-06
US20200270209A1 (en) 2020-08-27
PE20221579A1 (es) 2022-10-06
JP2018515495A (ja) 2018-06-14
US11827602B2 (en) 2023-11-28
AU2016259677A1 (en) 2017-10-26
UA121332C2 (uk) 2020-05-12
NZ736934A (en) 2023-11-24
MX2017014293A (es) 2018-08-09
CN111303000A (zh) 2020-06-19
JP2020125316A (ja) 2020-08-20
ZA202002435B (en) 2023-03-29
SMT202100367T1 (it) 2021-07-12
PE20180232A1 (es) 2018-01-31
JOP20210109A1 (ar) 2023-01-30
KR20180002644A (ko) 2018-01-08
UY36674A (es) 2016-11-30
EP3294738B1 (en) 2021-04-07
CR20170490A (es) 2018-03-08
CN113045476B (zh) 2024-07-16
PH12017502000B1 (en) 2018-03-26
ECSP22023220A (es) 2022-05-31
US10696632B2 (en) 2020-06-30
ES2941674T3 (es) 2023-05-24
JP7451626B2 (ja) 2024-03-18
US20180346419A1 (en) 2018-12-06
DK3294738T3 (da) 2021-06-28
SV2017005557A (es) 2018-06-26
NI201700137A (es) 2019-05-07
EA034978B1 (ru) 2020-04-14
SI3294738T1 (sl) 2021-08-31
UA128183C2 (uk) 2024-05-01
EA201792429A1 (ru) 2018-02-28
MX391754B (es) 2025-03-21
US20250230127A1 (en) 2025-07-17
HK1252446A1 (zh) 2019-05-24
IL272814A (en) 2020-04-30
JP2021138752A (ja) 2021-09-16
LT3294738T (lt) 2021-08-25

Similar Documents

Publication Publication Date Title
JOP20210109A1 (ar) مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20160198B1 (ar) مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20150335B1 (ar) مشتقات اندول بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20180025A1 (ar) مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
PH12017500571A1 (en) Mono-or di-substituted indole derivatives as dengue viral replication inhibitors
PH12018502015A1 (en) Substituted indole derivatives as dengue viral replication inhibitors
PH12018502077A1 (en) Substituted indoline derivatives as dengue viral replication inhibitors
JO3633B1 (ar) مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
PH12018502016A1 (en) Substituted indole derivatives as dengue viral replication inhibitors
CR20190531A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
PH12017500503A1 (en) Mono- or di-substituted indoles as dengue viral replication inhibitors
CR20190530A (es) Derivados de indolina sustituidos como inhibidores de la replicación viral de dengue
JOP20180026A1 (ar) مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
MY185672A (en) Mono-or di-substituted indole derivatives as dengue viral replication inhibitors
MY197383A (en) Mono- or di-substituted indole derivatives as dengue viral replication inhibitors